News Feature | Published:

Peering inside Alzheimer's brains

Nature Biotechnology volume 29, pages 384387 (2011) | Download Citation

Last year's failure of Eli Lilly's drug semagacestat in late-stage clinical trials was the latest in a long line of setbacks for novel Alzheimer's therapies. But advances in imaging and biomarker identification are providing added impetus to ongoing drug development. Gunjan Sinha reports.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Arch. Neurol. 67, 949–956 (2010).

  2. 2.

    et al. Arch. Gen. Psychiatry 67, 739–748 (2010).

  3. 3.

    et al. Nat. Genet. 41, 1094–1099 (2009).

  4. 4.

    et al. Nat. Genet. 41, 1088–1093 (2009).

  5. 5.

    et al. Ann. Neurol. 66, 48–54 (2009).

  6. 6.

    et al. Nature 467, 36–37 (2010).

  7. 7.

    et al. Science 330, 1774 (2010).

  8. 8.

    et al. Proc. Natl. Acad. Sci. USA 92, 12260–12264 (1995).

  9. 9.

    , et al. Mol. Psych. published online, doi:10.1038/mp.2010.123 (30 November 2010).

  10. 10.

    et al. PLoS Genet. 6, e1001101 (2010).

  11. 11.

    et al. Ann. Neurol. published online, doi:10.1002/ana.22343 (5 April 2011).

  12. 12.

    et al. J. Am. Med. Assoc. 305, 275–283 (2011).

Download references

Author information

Affiliations

  1. Berlin

    • Gunjan Sinha

Authors

  1. Search for Gunjan Sinha in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1863

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing